MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-07-2024
Alimera Sciences Cash Conversion Cycle 2011-2026 | ALIM
Annual Cash Conversion Cycle Alimera Sciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -128 | -201 | -167 | -124 | -182 | -174 | -351 | -560 | -348 | -795 | 107 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 107 | -795 | -266 |
Quarterly Cash Conversion Cycle Alimera Sciences
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -56.4 | -60.6 | - | -184 | -253 | - | -93.2 | -28.8 | -131 | - | -150 | -150 | -113 | - | -154 | -133 | -132 | - | -191 | -280 | -145 | - | -232 | -248 | 134 | 114 | 107 | 101 | 174 | 118 | 152 | 132 | 186 | 154 | 130 | 155 | 123 | 44.5 | 32.2 | 35.4 | 29.6 | - | 60.2 | 255 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 255 | -280 | -13.5 |
Cash Conversion Cycle of other stocks in the Drug manufacturers industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
460 | - | - | $ 754 M |  USA |
 |
Canopy Growth Corporation
CGC
|
177 | $ 1.11 | 4.25 % | $ 119 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-58.9 | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
110 | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-224 | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
41.4 | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
141 | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
-206 | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
45.7 | - | - | $ 36.6 M | USA |
 |
Evolus
EOLS
|
74.8 | $ 5.61 | 35.71 % | $ 362 M | USA |
 |
Cronos Group
CRON
|
213 | $ 2.66 | 2.31 % | $ 1.39 B | Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
192 | - | - | $ 2.06 B |  France |
 |
Harrow Health
HROW
|
18.3 | $ 39.84 | 3.2 % | $ 1.46 B | USA |
 |
Jupiter Wellness
JUPW
|
-21.1 | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
164 | $ 0.58 | 4.82 % | $ 10.1 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
-161 | $ 3.93 | -14.3 % | $ 55.3 M | USA |
 |
HEXO Corp.
HEXO
|
775 | - | 2.45 % | $ 38.1 M | Canada |
 |
Aurora Cannabis
ACB
|
1.45 K | $ 3.67 | 5.46 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
137 | - | -23.39 % | $ 1.76 M | USA |
 |
Organogenesis Holdings
ORGO
|
64.5 | $ 2.96 | 2.96 % | $ 390 M | USA |
 |
Emergent BioSolutions
EBS
|
181 | $ 8.93 | 0.17 % | $ 457 M | USA |
 |
ProPhase Labs
PRPH
|
96 | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
327 | $ 12.19 | 2.44 % | $ 866 M | USA |
 |
Radius Health
RDUS
|
-53.5 | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
78.9 | $ 5.65 | -1.4 % | $ 2.06 B | Canada |
 |
Lannett Company
LCI
|
173 | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
139 | - | -39.89 % | $ 27.7 M | USA |
 |
OrganiGram Holdings
OGI
|
2.92 K | $ 1.41 | 3.2 % | $ 402 M | Canada |
 |
Perrigo Company plc
PRGO
|
137 | $ 11.63 | 2.15 % | $ 1.61 B | USA |
 |
Rockwell Medical
RMTI
|
45 | $ 0.9 | 0.44 % | $ 21 M | USA |
 |
TherapeuticsMD
TXMD
|
-723 | $ 2.25 | 1.35 % | $ 23.5 M | USA |
 |
Pacira BioSciences
PCRX
|
209 | $ 22.89 | 3.57 % | $ 1.06 B | USA |
 |
Veru
VERU
|
6.7 | $ 2.6 | 3.17 % | $ 351 M | USA |
 |
PetIQ
PETQ
|
53.8 | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
314 | - | - | $ 1.08 B | USA |
 |
Viatris
VTRS
|
155 | $ 14.81 | -0.57 % | $ 17.8 B | USA |
 |
PLx Pharma
PLXP
|
111 | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
105 | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
92 | $ 0.74 | -3.77 % | $ 3.19 M | USA |
 |
SCYNEXIS
SCYX
|
106 | $ 0.76 | 0.96 % | $ 36.4 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
150 | $ 2.74 | -0.36 % | $ 3.4 M | USA |
 |
Tilray
TLRY
|
169 | $ 7.45 | 1.22 % | $ 4.6 B | Canada |